E.F. Hutton advises on Apimeds Pharmaceuticals and Mindwave Innovations merger.

E.F. Hutton served as exclusive M&A advisor in the merger between Apimeds Pharmaceuticals and Mindwave Innovations. The combined company will leverage a biotech development platform and AI-powered digital treasury infrastructure supported by a $100 million PIPE commitment. E.F. Hutton acted as placement agent for the PIPE commitment and worked closely with both companies to shape the transaction framework and coordinate the capital raise. The merger gives the combined business access to significant financing while integrating MindWave's AI-driven treasury engine.